EP1605935A4 - METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - Google Patents

METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Info

Publication number
EP1605935A4
EP1605935A4 EP04717992A EP04717992A EP1605935A4 EP 1605935 A4 EP1605935 A4 EP 1605935A4 EP 04717992 A EP04717992 A EP 04717992A EP 04717992 A EP04717992 A EP 04717992A EP 1605935 A4 EP1605935 A4 EP 1605935A4
Authority
EP
European Patent Office
Prior art keywords
disorders
compositions
management
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717992A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1605935A2 (en
Inventor
Peter H Schafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP1605935A2 publication Critical patent/EP1605935A2/en
Publication of EP1605935A4 publication Critical patent/EP1605935A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04717992A 2003-03-06 2004-03-05 METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Withdrawn EP1605935A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45237403P 2003-03-06 2003-03-06
US452374P 2003-03-06
PCT/US2004/006782 WO2004080393A2 (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Publications (2)

Publication Number Publication Date
EP1605935A2 EP1605935A2 (en) 2005-12-21
EP1605935A4 true EP1605935A4 (en) 2009-05-20

Family

ID=32990646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717992A Withdrawn EP1605935A4 (en) 2003-03-06 2004-03-05 METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Country Status (12)

Country Link
EP (1) EP1605935A4 (pt)
JP (1) JP2006519875A (pt)
KR (1) KR100831545B1 (pt)
CN (1) CN1780616B (pt)
AU (1) AU2004220607B2 (pt)
BR (1) BRPI0408113A (pt)
CA (1) CA2517845A1 (pt)
IL (1) IL170710A0 (pt)
MX (1) MXPA05009435A (pt)
NZ (1) NZ542408A (pt)
WO (1) WO2004080393A2 (pt)
ZA (1) ZA200507322B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
LT3697399T (lt) * 2017-10-18 2026-01-12 Intrabio Ltd Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2022098106A1 (ko) * 2020-11-04 2022-05-12 주식회사 오에이티씨 클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물
CN119280228B (zh) * 2024-11-06 2025-09-19 桂林医学院附属医院 帕金森病神经保护作用药物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001348A2 (en) * 1993-07-02 1995-01-12 Celgene Corporation Imides as inhibitors of tnp alpha
WO1997008143A1 (en) * 1995-08-29 1997-03-06 Celgene Corporation Inhibitors of tumor necrosis factor alpha
WO1999006041A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2005094218A2 (en) * 2004-03-05 2005-10-13 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
AR003951A1 (es) * 1995-05-26 1998-09-30 Pfizer Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla.
JP3568749B2 (ja) * 1996-12-17 2004-09-22 株式会社デンソー 半導体のドライエッチング方法
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR20050000400A (ko) * 2002-04-12 2005-01-03 셀진 코포레이션 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001348A2 (en) * 1993-07-02 1995-01-12 Celgene Corporation Imides as inhibitors of tnp alpha
WO1997008143A1 (en) * 1995-08-29 1997-03-06 Celgene Corporation Inhibitors of tumor necrosis factor alpha
WO1999006041A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2005094218A2 (en) * 2004-03-05 2005-10-13 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOGI M ET AL: "Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 165, no. 1-2, 3 January 1994 (1994-01-03), pages 208 - 210, XP024375768, ISSN: 0304-3940, [retrieved on 19940103] *
SRIRAM KRISHNAN ET AL: "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SEP 2002, vol. 16, no. 11, September 2002 (2002-09-01), pages 1474 - 1476, XP002522289, ISSN: 1530-6860 *

Also Published As

Publication number Publication date
CA2517845A1 (en) 2004-09-23
KR100831545B1 (ko) 2008-05-21
NZ542408A (en) 2009-03-31
WO2004080393A2 (en) 2004-09-23
BRPI0408113A (pt) 2006-03-01
CN1780616A (zh) 2006-05-31
KR20050109971A (ko) 2005-11-22
CN1780616B (zh) 2010-05-12
WO2004080393A3 (en) 2004-12-02
AU2004220607B2 (en) 2009-06-11
ZA200507322B (en) 2007-03-28
MXPA05009435A (es) 2005-11-23
AU2004220607A1 (en) 2004-09-23
EP1605935A2 (en) 2005-12-21
IL170710A0 (en) 2011-08-01
JP2006519875A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
IL175074A0 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatement, modification and management of pain
IL165258A0 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
HUP0501017A3 (en) Methods and compositions for treatment of central nervous system disorders
EP1567154A4 (en) METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
EP1699431A4 (en) COMPOSITIONS FOR THE TREATMENT OF EARLIER DISEASES AND APPLICATION PROCEDURES
ZA200503241B (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP1534295A4 (en) FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN
EP1605935A4 (en) METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
AU2003300409A1 (en) Word scramble games for stimulating brain and physical health
IL177861A0 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
IL179038A0 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1569903A4 (en) METHOD FOR THE USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS FOR THE TREATMENT AND SUPERVISION OF MYELOPROLIFERATIVE DISEASES AND COMPOSITIONS CONTAINING THESE MEDICAMENTS
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
EP1744748A4 (en) METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
EP1567148A4 (en) METHOD OF USE AND COMPOSITIONS WITH SELECTIVE CYTOKINE INHIBITORS FOR THE TREATMENT AND SUPPLEMENT OF MACULAR DEGENERATION
PL376756A1 (pl) Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP1746989A4 (en) METHODS OF USE AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITION MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES
AU2003202255A8 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ZA200610124B (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELGENE CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090421

17Q First examination report despatched

Effective date: 20091014

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101119